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I
ntroduction of Haemophilus influenzae type B (HiB) 
containing pentavalent vaccines (a combination vac-
cine which protects against five killer diseases- diph-
theria, pertussis, tetanus, hepatitis B and Haemophilus in-
fluenzae type B) in the Universal Immunization Program 
(UIP) was a far sighted decision taken in 2009 by the Min-
istry of Health and Family Welfare, Government of India. 
This decision was based on the recommendations of Na-
tional Technical Advisory 
Group on Immunization 
(NTAGI) and was aimed at 
reducing the burden of HiB 
related infections (1). The 
decision was supported by 
the GAVI Alliance (formerly 
known as the Global Alli-
ance for Vaccines and Immunizations) and in August 2009 
they decided to provide funding worth US$ 165 million to 
the Government of India to support the introduction of 
pentavalent vaccine (2). The vaccine was to be introduced 
in a phased manner. In the first phase, the vaccine would 
have been rolled-out in 10 states and an estimated 18 mil-
lion infants were expected to receive the vaccine. The de-
cision of the Indian Government to introduce HiB vaccina-
tion into its UIP was hailed internationally by public health 
practitioners as India constitutes 34% of the birth cohort 
in GAVI-eligible countries (3) and even in the absence of 
population-based data, the country is estimated to have the 
highest number of deaths due to HiB in children under 5 
years of age (4).
However, the plans to introduce the vaccine were stalled 
following the filing of a Public Interest Litigation (PIL) in 
the Delhi High Court in December 2010, which questioned 
rationale for introducing the vaccine as well as its efficacy 
(5). The petitioners, comprising of a mixed group of med-
ical practitioners including paediatricians, policy advisors 
to the Government of India, and a former civil servant (who 
also oppose the introduction of Hepatitis B vaccine into the 
UIP) claimed inter alia that the NTAGI had based its rec-
ommendation without considering data from studies which 
reveal that the burden of meningitis caused by HiB in In-
dian children is much lower 
than in other parts of the 
world (6, 7). Moreover, the 
petitioners claimed that re-
cent evidence from coun-
tries which have used pen-
tavalent vaccine for several 
years revealed that there was 
no real benefit to children (8). They also claimed that the 
vaccine had been withdrawn from neighbouring Bhutan 
and Sri Lanka after reports of adverse effects following im-
munization with the vaccine. The Delhi High court sought 
a reply from the Indian Council of Medical Research 
(ICMR), NTAGI and Indian Ministry of Health (9). Under 
increasing pressure, the government decided to halt the in-
troduction of the vaccine and set up an expert committee 
to review all the available evidence on the HiB disease bur-
den, assess the need for introducing pentavalent vaccine as 
a part of UIP and review the possible adverse effects. Al-
though the findings of the expert committee have not been 
made public, recent reports in the media indicate that the 
Indian Government plans to introduce the vaccine in two 
South Indian states (Tamil Nadu and Kerala) in September 
2011 (10,11). Amidst all this controversy, it is justified to 
question if the objections raised by the petitioners were 
based on sound evidence.
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Petitioners in High Court cite low disease 
burden due to Hib and safety concerns as 
main reasons for opposing the introduction 
of the vaccine.
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In the absence of surveillance data or good quality com-
munity based studies with active ascertainment of cases of 
invasive HiB disease to base the burden of disease estimate 
in India, the only option is to use data derived from hospi-
tal – based studies with passive case ascertainment and 
mathematical models based on systematic literature review 
and vaccine probe studies. Using the latter approach, Watt 
and colleagues estimated the burden of invasive HiB dis-
ease (which includes pneumonia and meningitis) in India 
in 2000 to be about 2.4 million cases with 72 000 deaths 
in children aged less than 5 years, which accounted for ap-
proximately 4% of all child deaths in India (4). It is well 
acknowledged that the incidence of pneumonia far exceeds 
meningitis while the latter has a higher case fatality ratio. 
In 2008, Rudan and colleagues estimated that in India, 43 
million new cases of clinical pneumonia in children under 
the age of 5 years occur each year and result in 408 000 
deaths (12). Using the estimates from the HiB study (4), 
we estimate that around 215 000 new cases of HiB pneu-
monia occur yearly in Indian children under the age of 5 
years and result in over 61 000 deaths. Thus, studies have 
consistently projected the burden of HiB disease in India 
to be significant. The studies cited by the petitioners (7, 
13) have serious limitations, making it extremely difficult 
to generalise the results to the Indian population as a whole 
– the studies were conducted more than 15 years ago in an 
area which had, even at that time, less than half the infant 
mortality rate compared to the Indian average; the investi-
gators only looked at HiB meningitis as an outcome; and 
have themselves concluded that “these estimates are mini-
mal” (7). However, in the light of the present controversy, 
it may be worthwhile to conduct a systematic literature re-
view of Indian studies to estimate the burden of HiB relat-
ed acute bacterial pneumonia and meningitis in India to 
provide a clearer picture. 
The concerns raised regarding the adverse effects of the 
pentavalent vaccine appear to be unsubstantiated. The 
World Health Organization had established a panel of in-
ternational experts to examine the reports of hypotonic-
hyporesponsive episodes (HHEs) following administration 
of the pentavalent vaccine (HHE is a recognized adverse 
reaction to whole-cell and acellular pertussis-containing 
vaccines, and to HiB and hepatitis B vaccines). The expert 
panel concluded that there was no evidence to establish a 
causal relationship between pentavalent vaccine and any 
of the deaths reported following its administration (14). It 
also concluded that “the reporting rate of HHE following 
the pentavalent vaccine (14.9 cases per 100 000 doses) was 
found to be well within the reported estimates of HHE fol-
lowing whole-cell pertussis-containing vaccines (21–250 
cases per 100 000 doses).” Following this, the Sri Lankan 
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government decided to re-introduce the vaccine from Sep-
tember 2009. However, due to shortage of fresh stocks this 
was only possible in February 2010 (15).
Contrary to the remarks on the lack of beneficial effects of 
the vaccine, 150 countries across the globe that have al-
ready introduced HiB vaccine have reported a dramatic de-
cline in the incidence of invasive HiB disease and death. 
Morris and colleagues in a systematic review of the effec-
tiveness of HiB vaccine demonstrated that HiB conjugate 
vaccines were highly effective in reducing the incidence of 
invasive HiB disease, with similar effectiveness seen across 
geographical regions and different levels of socioeconomic 
development. (16) Even in countries which have poor im-
munization coverage, indirect benefits of the vaccine have 
been reported due to the herd effect. For instance, data 
from Gambia have shown the benefits of herd immunity 
even when vaccine coverage has been below 60% (17). The 
vaccine should thus be effective in India where UIP cover-
age is poor. In fact, long before the NTAGI recommended 
introduction of HiB vaccine into the UIP, the Indian Acad-
emy of Pediatrics had called for incorporating the vaccine 
into the UIP (18).
The Cochrane study which has been cited by the petition-
ers to show that there is no benefit of a combination vaccine 
in terms of disease burden reduction and immunogenicity 
found that no studies reported the primary outcome for the 
study ie, incidence of disease (8). The authors themselves 
conclude that “[T]he results of this review should be viewed 
with caution, mostly as an indication that high quality data 
are lacking.” Moreover, Dutta and colleagues recently car-
ried out a phase-III multicentric trial of the pentavalent vac-
cine and found that the combination vaccine had a high 
immunogenicity and was well tolerated (19). In resource-
poor settings like India, decisions to use the vaccine are ex-
pected to be guided by the cost associated with its introduc-
tion. While the concerns regarding the costs are legitimate, 
recent data suggest that the cost of the vaccine has reduced 
substantially. At present there are at least five Indian com-
panies manufacturing the vaccine. With one of the Indian 
manufacturers, the Serum Institute of India, announcing in 
June 2011 that they plan to sell the vaccine at US$ 1.75 (€ 
1.2) per dose, it is expected that the other manufacturers 
will follow suit (20). In the future the price will reduce even 
further – as a result of bulk procurement by the Govern-
ment and competition between the manufacturers. It has 
already been demonstrated that any price lower than US$ 
2 (€ 1.4) per dose is highly cost effective (21).
The concerns regarding the introduction of a new vaccine 
on an already overwhelmed public health system in India 
appear to be valid. However, experience from other devel-
oping countries suggests that it is feasible despite limited 
resources (22). Further, it may not be inappropriate to as-
sume that the opportunity offered by the introduction of a 
new vaccine may provide the desired boost to the health 
system through refresher trainings to the health workers 
and generating demand among parents and caregivers and 
may lead to an improvement in the routine immunization 
coverage especially in the North Indian states. Hence, while 
the decision regarding GAVI Alliance’s efforts to introduce 
the pentavalent vaccine in India seems to be centred around 
debates regarding the associated commercial consider-
ations, it may be prudent to focus more on the long-term 
benefits of the vaccine and its potential to reduce mortality 
and morbidity amongst children aged less than 5 years, 
bringing the country closer to Millennuim Development 
Goal 4. 
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